Multicenter comparison of the Vitek 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing caspofungin, micafungin, and posaconazole against Candida spp.

Journal of Clinical Microbiology

Volumn 49, Issue 5, 2011, Pages 1765-1771

  Peterson, Jess F ^a   Pfaller, Michael A ^c   Diekema, Daniel J ^c   Rinaldi, Michael G ^d   Riebe, Katherine M ^b   Ledeboer, Nathan A ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b DYNACARE LABORATORIES   (Canada)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MICAFUNGIN; POSACONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA HAEMULONII; CANDIDA KRUSEI; CANDIDA NORVEGENSIS; CANDIDA PARAPSILOSIS; CANDIDA RUGOSA; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CONTROLLED STUDY; FUNGAL STRAIN; INTERMETHOD COMPARISON; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA ANOMALA; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; REPRODUCIBILITY;

ANTIFUNGAL AGENTS; AUTOMATION; CANDIDA; ECHINOCANDINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; TRIAZOLES; UNITED STATES;

CANDIDA; CANDIDA ALBICANS;

EID: 79955527633     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02517-10     Document Type: Article

References (24)

1. Alexander, B. D., et al. 2007. Comparative evaluation of Etest and Sensititre YeastOne panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J. Clin. Microbiol. 45:698-706.
2. Almirante, B., et al. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
3. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeast, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
5. Diekema, D. J., et al. 2007. Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates on Candida spp. against posaconazole. J. Clin. Microbiol. 45:1974-1977.
6. Fridkin, S. K. 2005. The changing face of fungal infections in health care setting. Clin. Infect. Dis. 41:1455-1460.
7. Gudlaugsson, O., et al. 2003. Attributable mortality of nosocomial candidemia, revisited. Clin. Infect. Dis. 37:1172-1177.
8. Hidron, A. I., et al. 2008. Antimicrobial-resistant pathogens associated with health-care associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention 2006-2007. Infect. Control Hosp. Epidemiol. 29:996-1011.
9. Mora-Duarte, J., et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
10. Morgan, J., et al. 2005. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect. Control Hosp. Epidemiol. 26:540-547.
11. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
12. Pappas, P. G., et al. 2003. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis. 37:634-643.
13. Pappas, P. G., et al. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
14. Pappas, P. G., et al. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
15. Pfaller, M. A., et al. 2008. Clinical evaluation of the Sensititre YeastOne colorimetric antifungal panel for antifungal susceptibility testing of the echinocandins anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 46:2155-2159.
16. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
17. Pfaller, M. A., et al. 23 February 2011, posting date. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. [Epub ahead of print.]
18. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J. Clin. Microbiol. 45:796-802.
19. Pfaller, M. A., D. J. Diekema, G. W. Procop, and M. G. Rinaldi. 2007. Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J. Clin. Microbiol. 45: 3522-3528.
20. Pfaller, M. A., et al. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559.
21. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmstom, and R. N. Jones. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. J. Clin. Microbiol. 39: 4387-4389.
22. Sims, C. R., V. L. Paetznick, J. R. Rodriguez, E. Chen, and L. Ostrosky-Zeichner. 2006. Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J. Clin. Microbiol. 44:2105-2108.
23. Ullmann, A. J., et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347.
24. Van Burik, J. H., et al. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-1416.